Congress must investigate Pfizer’s other dangerous boondoggle: Paxlovid

by | Jan 13, 2023


Where is the intellectual curiosity of millions of doctors who blindly supported expensive, experimental products without circumspection, but scoffed at every cheap, safe, and long-standing approved therapeutic to treat COVID? Whether the medical community finds its spiritual catharsis or not, House Republicans need to engage in oversight of the shots, remdesivir, and Paxlovid – including their side effects, what led to their expedited approval and purchase by the federal government, and how we stop this from happening in the future.

It’s the other novel therapy that was supposed to pick up the slack for when the gene therapy shots failed. Our government purchased, without question, billions of dollars’ worth of Pfizer’s new drug, Paxlovid, without any independent studies vouching for its safety, even though its ritonavir component is an AIDS drug contraindicated with 32 common drug categories taken by seniors, such as statins and steroids. Officials also approved it while dissing ivermectin, which uses Paxlovid’s mechanism as a protease inhibitor … plus another 19 mechanisms of action.

Now, the more we discover problems with the jabs, we’re also finding out the problems with Pfizer’s Paxlovid, which is so unquestionably supported that the FDA allowed pharmacies to dispense it without a doctor’s prescription (while denying fully approved drugs prescribed by doctors). Despite the already known and questionable issues with safety and the “rebound” effect of Paxlovid, the Department of Defense paid Pfizer $2 billion in December for another 3.7 million courses of the drug ($540 per course). This is on top of the existing $10.6 billion for the original 20 million courses. Pfizer is expected to earn $22 billion from this drug on the backs of taxpayers. For some perspective, Home Depot’s net revenue in 2021 was $16.4 billion.

There is quite literally no other drug that has been accorded such status and backing, especially an experimental drug. But it’s the job of the House Oversight’s Select Subcommittee on the Coronavirus Pandemic to answer the question as to why this drug is still being treated like a hero and not a zero – or worse. In December, researchers from University of Iowa Hospitals and Clinics reported in a case study that a 67-year-old woman who was taking tacrolimus as part of her immunosuppressive regimen for her organ transplant suffered a severe injury to her kidney as a result of the contraindication of Paxlovid.

Read the rest here.


  • Daniel Horowitz

    Daniel Horowitz is a senior editor of TheBlaze and host of the Conservative Review podcast. He writes on the most decisive battleground issues of our times, including the theft of American sovereignty through illegal immigration, the theft of American liberty through tyranny, and the theft of American law and order through criminal justice "reform."

    View all posts